HK1040064B - 用以治療HIV(人類免疫缺陷病毒)感染的β-D-2'， 3'-雙去氫-2'， 3'-雙去氟-5-氟胞苷 - Google Patents

用以治療HIV(人類免疫缺陷病毒)感染的β-D-2'， 3'-雙去氫-2'， 3'-雙去氟-5-氟胞苷

Info

Publication number
HK1040064B
HK1040064B HK02101840.8A HK02101840A HK1040064B HK 1040064 B HK1040064 B HK 1040064B HK 02101840 A HK02101840 A HK 02101840A HK 1040064 B HK1040064 B HK 1040064B
Authority
HK
Hong Kong
Prior art keywords
beta
d4fc
hiv
fluorocytidine
didehydro
Prior art date
Application number
HK02101840.8A
Other languages
English (en)
Other versions
HK1040064A1 (en
Inventor
Raymond F Schinazi
Jennifer Hammond
John W Mellors
Dennis C Liotta
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of HK1040064A1 publication Critical patent/HK1040064A1/xx
Publication of HK1040064B publication Critical patent/HK1040064B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK02101840.8A 1999-01-22 2002-03-11 用以治療HIV(人類免疫缺陷病毒)感染的β-D-2'， 3'-雙去氫-2'， 3'-雙去氟-5-氟胞苷 HK1040064B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11677399P 1999-01-22 1999-01-22
PCT/US2000/001738 WO2000043014A2 (en) 1999-01-22 2000-01-21 Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections

Publications (2)

Publication Number Publication Date
HK1040064A1 HK1040064A1 (en) 2002-05-24
HK1040064B true HK1040064B (zh) 2006-07-21

Family

ID=22369127

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02101840.8A HK1040064B (zh) 1999-01-22 2002-03-11 用以治療HIV(人類免疫缺陷病毒)感染的β-D-2'， 3'-雙去氫-2'， 3'-雙去氟-5-氟胞苷

Country Status (21)

Country Link
EP (1) EP1143976B9 (zh)
JP (1) JP2002535278A (zh)
KR (1) KR100745408B1 (zh)
CN (2) CN1337880A (zh)
AT (1) ATE324894T1 (zh)
AU (1) AU781281B2 (zh)
BR (1) BR0007627A (zh)
CA (1) CA2360039C (zh)
DE (1) DE60027691T2 (zh)
DK (1) DK1143976T3 (zh)
ES (1) ES2263449T3 (zh)
HK (1) HK1040064B (zh)
IL (1) IL144382A (zh)
MX (1) MXPA01007359A (zh)
NO (1) NO323586B1 (zh)
NZ (1) NZ528156A (zh)
PL (1) PL198237B1 (zh)
PT (1) PT1143976E (zh)
RU (1) RU2254133C2 (zh)
WO (1) WO2000043014A2 (zh)
ZA (1) ZA200105971B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084627A1 (en) * 2002-06-27 2006-04-20 Medivir Ab Synergistic interaction of abacavir and alovudine
US20050244490A1 (en) * 2003-12-09 2005-11-03 Michael Otto Dosing methods for beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
WO2005097618A2 (en) 2004-04-01 2005-10-20 Achillion Pharmaceuticals, Inc. Low dose therapy for treating viral infections
WO2006044968A2 (en) * 2004-10-19 2006-04-27 Achillion Pharmaceuticals, Inc. Combination therapy for treating viral infections
US8091224B2 (en) * 2008-10-06 2012-01-10 GE Intelligent Platforms Embedded Systems, Inc. Method for coupling a battery within an embedded system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8901258A (nl) * 1989-05-19 1990-12-17 Stichting Rega V Z W 5-halogeno-2',3'-dideoxycytidinederivaten in geneesmiddelen voor het behandelen van retrovirus-infecties.
FR2729390A1 (fr) * 1995-01-18 1996-07-19 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
US6194391B1 (en) * 1998-06-24 2001-02-27 Emory University 3′-azido-2′,3′-dideoxyuridine administration to treat HIV and related test protocol

Also Published As

Publication number Publication date
KR20020068260A (ko) 2002-08-27
NO323586B1 (no) 2007-06-11
MXPA01007359A (es) 2003-09-22
DE60027691T2 (de) 2007-04-12
PL198237B1 (pl) 2008-06-30
ZA200105971B (en) 2002-10-21
WO2000043014A2 (en) 2000-07-27
IL144382A0 (en) 2002-05-23
AU781281B2 (en) 2005-05-12
ATE324894T1 (de) 2006-06-15
HK1040064A1 (en) 2002-05-24
WO2000043014A3 (en) 2000-11-30
EP1143976A2 (en) 2001-10-17
WO2000043014A8 (en) 2001-01-18
IL144382A (en) 2007-02-11
CN101219148A (zh) 2008-07-16
JP2002535278A (ja) 2002-10-22
CA2360039C (en) 2009-11-24
AU2627000A (en) 2000-08-07
DE60027691D1 (de) 2006-06-08
BR0007627A (pt) 2002-04-09
EP1143976B9 (en) 2007-02-14
NO20013599D0 (no) 2001-07-20
CA2360039A1 (en) 2000-07-27
EP1143976B1 (en) 2006-05-03
PT1143976E (pt) 2006-09-29
ES2263449T3 (es) 2006-12-16
KR100745408B1 (ko) 2007-08-02
NO20013599L (no) 2001-09-20
NZ528156A (en) 2005-03-24
CN1337880A (zh) 2002-02-27
RU2254133C2 (ru) 2005-06-20
DK1143976T3 (da) 2006-09-04

Similar Documents

Publication Publication Date Title
MXPA00012842A (es) Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
HUP0300027A2 (en) Nucleoside analogs with carboxamidine modified monocyclic base and process for their use
TW371660B (en) Therapeutic nucleosides a purine carbocyclic nucleosides for treatment of HIV and HBV infections
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
UA40589C2 (uk) Спосіб лікування людини, що страждає від вірусної інфекції, фармацевтична композиція, комбінація речовин для отримання ліків та фармацевтична комбінація
UA29429C2 (uk) Фармацевтична композиція для лікування вірусних інфекцій, спосіб отримання композиції, спосіб лікування або профілактики віл-інфекції у людини
AP2000001991A0 (en) 3-(Amino-or aminoalkyl) pyridinone derivatives and their use for the treatment of HIV related diseases.
JP2002528502A5 (zh)
KR880007079A (ko) 레트로비루스에 감염된 환자치료에 있어서의 3'-디옥시티미딘-2'-엔(3'-디옥시-2',3'-디디하이드로티미딘)의 사용법
MY124465A (en) Reduction of infarct volume using citicoline
CO5251425A1 (es) Metodo y composiciones para administrar taxanos oralmente a pacientes humanos
JP2003514025A5 (zh)
HK1040064A1 (en) Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections
GB9023701D0 (en) Medical treatment
MY105855A (en) Therapeutic nucleotides.
ES2148234T3 (es) Composicion farmaceutica a base de flavopereirina y su utilizacion en el tratamiento del virus vih.
ATE297732T1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
ES2233101T3 (es) Dosis unitaria de fgf-2 angiogenicamente efectiva y su utilizacion.
KR860003018A (ko) 1-β-D-리보푸라노실-1,2,4-트리아졸-3-카르복사미드를 이용한 인체의 비루스성 질환의 의학적 치료방법
EP1731155A3 (en) Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine for use in the treatment of hiv infections
WO1990005523A3 (en) Phenanthrolinedicarboxylate esters, 4-aminoquinoline and isoquinoline derivatives as inhibitors of hiv reverse transcriptase
DE60025826D1 (de) Pyrazolidinol-verbindungen
James PMPA--first human results
Prescott Antimicrobial agents and chemotherapy: highlights of the 38th Interscience Conference
Gilden IL-2 taken to HAART

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110121